Hoping to create a one-stop shop for all of farmers’ crop-growing and protection needs, the German chemical giant Bayer has purchased St. Louis-based Monsanto Co., which produces genetically-modified seeds for growing crops. The deal is valued at $66 billion, which comes out to about $128 per share.
Most probably know Bayer for drugs like aspirin and Alka-Seltzer, but it also has a thriving pesticide business. With the acquisition of Monsanto, which is the biggest supplier of genetically-modified seeds in the world, Bayer will become a massive agricultural force able to provide farmers with seeds for their crops, the sprays needed to protect them, and advice on how to best use all the products. Bayer hopes that, in the long term, the move will put them at the forefront of sustaining the world’s growing population on high-tech crops.
Who are the winners and losers in this deal? How, if at all, will this acquisition translate into the prices consumers see in the grocery store? What could the long-term impact of the acquisition be?